Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 3.2M | 27.7% |
| Gross Profit | -6.9M | 3.5% |
| Cost of Revenue | 10M | 10.1% |
| Operating expense | 55M | 13.3% |
| Net Income | -52M | 12.5% |
| EBITDA | -42M | 7.5% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 823M | 2.6% |
| Total Liabilities | 37M | 16.7% |
| Total Equity | 786M | 3.4% |
| Shares Outstanding | 66M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -55M | 88.3% |
| Cash from investing | 48M | 202.2% |
| Cash from financing | 1.2M | 66.6% |
EPS
Financial Highlights for Celldex Therapeutics in Q3 '24
Celldex Therapeutics reported a revenue of 3.2M, which is a 27.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -6.9M, marking a -3.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 10M, a 10.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 55M, showing a 13.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -52M, showing a -12.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -42M, showing a 7.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Celldex Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
